Most researchers trying to source CJC-1295 in Koah quickly find that local retail options are essentially nonexistent. This online-only market structure is actually an advantage for quality — top vendors compete on lab-verified purity in ways no local retailer can match. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Koah researcher needs to source confidently.
The Science Behind CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Koah studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate CJC-1295 Vendors
Vetting CJC-1295 vendors starts with the COA: locate the batch-specific certificate prior to buying, not after. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are within acceptable research limits. Community reputation in research forums is a valuable complement to COA verification — vendors with consistently positive reports over 12+ months have proved themselves through consistent results. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Koah
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and restricted human research data. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — or 25mcg per insulin syringe unit. Bacterial endotoxin contamination is the primary safety concern specific to research peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is unapproved for human therapeutic application and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.